FIG 10.

Metabolite-mediated potentiation of NIT activity against UPEC. Stationary-phase UPEC strains CFT073 and UTI89 were treated with DMSO, 250 μg/ml NIT, 10 mM glucose, or NIT supplemented with glucose (A and B). (C and D) Treatments were carried out as in panel A, except that 10 mM mannitol was used instead of glucose. CFU were determined at the indicated time points. *, P < 0.05 (t test), comparing NIT with either glucose plus NIT or mannitol plus NIT. Data represent at least three biological replicates. Each data point was denoted as mean ± SE.